{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:49:43Z","timestamp":1735883383741,"version":"3.32.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.7759\/cureus.76813","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T23:28:55Z","timestamp":1735860535000},"source":"Crossref","is-referenced-by-count":0,"title":["Self-Organizing Map-Based Assessment of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors"],"prefix":"10.7759","author":[{"given":"Satoshi","family":"Nakao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koumi","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakiko","family":"Hirofuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanaka","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Nokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Sugishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayako","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.014.10122","article-title":"Immune checkpoint inhibitors in clinical trials","volume":"33","author":"Sharon E","year":"2014","unstructured":"Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014, 33:434-44. 10.5732\/cjc.014.10122","journal-title":"Chin J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang SJ","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023, 9:543-53. 10.1016\/j.trecan.2023.04.002","journal-title":"Trends Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.02.011","article-title":"Toxicity patterns with immunomodulating antibodies and their combinations","volume":"42","author":"Haanen JB","year":"2015","unstructured":"Haanen JB, Thienen Hv, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015, 42:423-8. 10.1053\/j.seminoncol.2015.02.011","journal-title":"Semin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-related adverse events: a case-based approach","volume":"9","author":"Connolly C","year":"2019","unstructured":"Connolly C, Bambhania K, Naidoo J. Immune-related adverse events: a case-based approach. Front Oncol. 2019, 9:530. 10.3389\/fonc.2019.00530","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja L","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017, 28:2377-85. 10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel JC","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, et al.. Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017, 57:36-49. 10.1016\/j.ctrv.2017.05.003","journal-title":"Cancer Treat Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni A","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022, 13:779691. 10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","author":"Kartolo A","year":"2018","unstructured":"Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol. 2018, 25:e403-10. 10.3747\/co.25.4047","journal-title":"Curr Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/20420986221101963","article-title":"Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database","volume":"13","author":"Yoshida Y","year":"2022","unstructured":"Yoshida Y, Sasaoka S, Tanaka M, et al.. Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database. Ther Adv Drug Saf. 2022, 13:20420986221101963. 10.1177\/20420986221101963","journal-title":"Ther Adv Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21891","article-title":"Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system","volume":"9","author":"Hirofuji S","year":"2023","unstructured":"Hirofuji S, Miyasaka K, Maezawa M, et al.. Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system. Heliyon. 2023, 9:e21891. 10.1016\/j.heliyon.2023.e21891","journal-title":"Heliyon"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190102","article-title":"Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database","volume":"12","author":"Abe J","year":"2017","unstructured":"Abe J, Umetsu R, Uranishi H, et al.. Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. PLoS One. 2017, 12:e0190102. 10.1371\/journal.pone.0190102","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04542-7","article-title":"Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database","volume":"92","author":"Oura M","year":"2023","unstructured":"Oura M, Oguro F, Agatsuma N, Imamaki H, Nishikawa Y. Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database. Cancer Chemother Pharmacol. 2023, 92:7-14. 10.1007\/s00280-023-04542-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-017-0088-5","article-title":"Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases","volume":"3","author":"Hatahira H","year":"2017","unstructured":"Hatahira H, Abe J, Hane Y, et al.. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. J Pharm Health Care Sci. 2017, 3:19. 10.1186\/s40780-017-0088-5","journal-title":"J Pharm Health Care Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000549","article-title":"Identification of drugs and patient profiles at risk for severe skin injuries due to extravasation. Analysis of a spontaneous reporting system","volume":"47","author":"Maezawa M","year":"2024","unstructured":"Maezawa M, Miyasaka K, Hirofuji S, et al.. Identification of drugs and patient profiles at risk for severe skin injuries due to extravasation. Analysis of a spontaneous reporting system. J Infus Nurs. 2024, 47:233-48. 10.1097\/NAN.0000000000000549","journal-title":"J Infus Nurs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121299","article-title":"Exploring the mechanisms underlying drug-induced fractures using the Japanese Adverse Drug Event Reporting database","volume":"14","author":"Toriumi S","year":"2021","unstructured":"Toriumi S, Kobayashi A, Sueki H, Yamamoto M, Uesawa Y. Exploring the mechanisms underlying drug-induced fractures using the Japanese Adverse Drug Event Reporting database. Pharmaceuticals (Basel). 2021, 14:1299. 10.3390\/ph14121299","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-00784-6","article-title":"Self-Organization and Associative Memory","author":"Kohonen T","year":"1988","unstructured":"Kohonen T. Self-Organization and Associative Memory. Springer-Verlag, Berlin; 1988. 10.1007\/978-3-662-00784-6"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.13-00201","article-title":"Visualization and analysis of drug information on adverse reactions using data mining method, and its clinical application [Article in Japanese]","volume":"134","author":"Kawakami J","year":"2014","unstructured":"Kawakami J. Visualization and analysis of drug information on adverse reactions using data mining method, and its clinical application [Article in Japanese]. Yakugaku Zasshi. 2014, 134:105-18. 10.1248\/yakushi.13-00201","journal-title":"Yakugaku Zasshi"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.14-00145","article-title":"Visualization and analysis of adverse reactions of molecularly targeted anticancer agents using the self-organizing map (SOM) [Article in Japanese]","volume":"134","author":"Hamamoto T","year":"2014","unstructured":"Hamamoto T, Serizawa A, Ohtsuki K, Kawakami J, Sato K. Visualization and analysis of adverse reactions of molecularly targeted anticancer agents using the self-organizing map (SOM) [Article in Japanese]. Yakugaku Zasshi. 2014, 134:1069-80. 10.1248\/yakushi.14-00145","journal-title":"Yakugaku Zasshi"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68260","article-title":"Evaluation of antipsychotic-induced neuroleptic malignant syndrome using a self-organizing map","volume":"16","author":"Miyasaka K","year":"2024","unstructured":"Miyasaka K, Hirofuji S, Maezawa M, et al.. Evaluation of antipsychotic-induced neuroleptic malignant syndrome using a self-organizing map. Cureus. 2024, 16:e68260. 10.7759\/cureus.68260","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2011.08.002","article-title":"In silico prediction of rhabdomyolysis of compounds by self-organizing map and support vector machine","volume":"25","author":"Hu X","year":"2011","unstructured":"Hu X, Yan A. In silico prediction of rhabdomyolysis of compounds by self-organizing map and support vector machine. Toxicol In Vitro. 2011, 25:2017-24. 10.1016\/j.tiv.2011.08.002","journal-title":"Toxicol In Vitro"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5772\/50095","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi E","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, Ponti FD. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). Data Mining Applications in Engineering and Medicine. Karahoca A (ed): InTechOpen, Rijeka; 2012. 265-302. 10.5772\/50095"},{"key":"ref24","unstructured":"Drug adverse reaction database. terms of use [In Japanese]. (2024). Accessed: December 24, 2024: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0003.html."},{"key":"ref25","unstructured":"Pharmaceutical and Medical Device Regulatory Science Society of Japan. Medical Dictionary for Regulatory Activities (MedDRA\/J) [In Japanese]. (2024). Accessed: October 6, 2024: https:\/\/www.jmo.pmrj.jp\/."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5108","article-title":"Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database","volume":"29","author":"Hasegawa S","year":"2020","unstructured":"Hasegawa S, Ikesue H, Nakao S, et al.. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 2020, 29:1279-94. 10.1002\/pds.5108","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber JS","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015, 33:2092-9. 10.1200\/JCO.2014.60.0379","journal-title":"J Clin Oncol"},{"key":"ref28","unstructured":"Bristol-Myers Squibb K.K. YERVOY\u00ae package insert [In Japanese]. (2024). Accessed: October 6, 2024: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291430."},{"key":"ref29","unstructured":"Regeneron Pharmaceuticals, Inc.. Libtayo\u00ae package insert [In Japanese]. (2024). Accessed: October 6, 2024: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291466."},{"key":"ref30","unstructured":"ONO PHARMACEUTICAL CO., LTD. OPDIVO\u00ae package insert [In Japanese]. (2024). Accessed: October 6, 2024: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291427."},{"key":"ref31","unstructured":"AstraZeneca K.K.. IMFINZI\u00ae package insert [in Japanese]. (2023). Accessed: October 6, 2024: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291443."},{"key":"ref32","unstructured":"AstraZeneca K.K.. IMJUDO\u00ae package insert [In Japanese]. (2023). Accessed: October 6, 2024: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291465."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS","volume":"39","author":"Ji HH","year":"2019","unstructured":"Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig. 2019, 39:319-30. 10.1007\/s40261-018-0735-0","journal-title":"Clin Drug Investig"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017, 377:1345-56. 10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima H","year":"2019","unstructured":"Arima H, Iwama S, Inaba H, et al.. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr J. 2019, 66:581-6. 10.1507\/endocrj.EJ19-0163","journal-title":"Endocr J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.11256\/jjdi.17.125","article-title":"Association between antipsychotic use and extrapyramidal syndrome. Data mining of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report database","volume":"17","author":"Hosomi K","year":"2015","unstructured":"Hosomi K, Park B, Inose R, Fujimoto M, Takada M. Association between antipsychotic use and extrapyramidal syndrome. Data mining of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report database. Jpn J Drug Inform. 2015, 17:125-32. 10.11256\/jjdi.17.125","journal-title":"Jpn J Drug Inform"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek EP","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002, 11:3-10. 10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1248\/bpbreports.7.3_76","article-title":"Analysis of metformin-associated lactic acidosis using Japanese Adverse Drug Event Report database","volume":"3","author":"Ichihara N","year":"2024","unstructured":"Ichihara N, Maezawa M, Nakao S, et al.. Analysis of metformin-associated lactic acidosis using Japanese Adverse Drug Event Report database. BPB Reports. 2024, 3:76-80. 10.1248\/bpbreports.7.3_76","journal-title":"BPB Reports"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-024-04428-y","article-title":"Analysis of drug-induced interstitial lung disease caused by herbal medicine using the Japanese Adverse Drug Event Report database","volume":"24","author":"Oura K","year":"2024","unstructured":"Oura K, Tanaka M, Matsumoto K, et al.. Analysis of drug-induced interstitial lung disease caused by herbal medicine using the Japanese Adverse Drug Event Report database. BMC Complement Med Ther. 2024, 24:121. 10.1186\/s12906-024-04428-y","journal-title":"BMC Complement Med Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12790","article-title":"Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases","volume":"44","author":"Mukai R","year":"2019","unstructured":"Mukai R, Hasegawa S, Umetsu R, et al.. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases. J Clin Pharm Ther. 2019, 44:285-91. 10.1111\/jcpt.12790","journal-title":"J Clin Pharm Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami T","year":"2021","unstructured":"Mikami T, Liaw B, Asada M, et al.. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021, 152:135-44. 10.1007\/s11060-020-03687-2","journal-title":"J Neurooncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen C","year":"2021","unstructured":"Chen C, Wu B, Zhang C, Xu T. Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol. 2021, 95:107498. 10.1016\/j.intimp.2021.107498","journal-title":"Int Immunopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/322122-self-organizing-map-based-assessment-of-immune-related-adverse-events-caused-by-immune-checkpoint-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T23:28:59Z","timestamp":1735860539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/322122-self-organizing-map-based-assessment-of-immune-related-adverse-events-caused-by-immune-checkpoint-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.76813","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}